Skip to content
10-Q

Quarterly Report

C4 Therapeutics, Inc. CCCC

0001628280-25-022866

← back to feed
Filed
May 7, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 71.01M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $40.82M
Current Liabilities Q1 2025 · Dec 31, 2024 $45.18M
Total Liabilities Q1 2025 · Mar 31, 2025 $124.38M
Total Liabilities Q1 2025 · Dec 31, 2024 $133.62M
Current Assets Q1 2025 · Mar 31, 2025 $232.54M
Current Assets Q1 2025 · Dec 31, 2024 $257.77M
Total Assets Q1 2025 · Mar 31, 2025 $319.52M
Total Assets Q1 2025 · Dec 31, 2024 $349.6M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $55.5M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $89.66M
Shares Diluted Q1 2025 · Mar 31, 2024 68.43M sh
Stock Repurchased Q1 2025 · Mar 31, 2024 $109K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$18.12M
Stockholders Equity Q1 2025 · Mar 31, 2024 $258.28M
Stockholders Equity Q1 2025 · Dec 31, 2023 $246.11M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.41
Eps Basic Q1 2025 · Mar 31, 2024 −$0.41
Sga Expense Q1 2025 · Mar 31, 2024 $10.29M
Rd Expense Q1 2025 · Mar 31, 2024 $22.53M
Net Income Q1 2025 · Mar 31, 2024 −$28.36M
Operating Income Q1 2025 · Mar 31, 2024 −$32.22M
Revenue Q1 2025 · Mar 31, 2024 $3.04M